EGFR and non-small cell lung carcinoma: Treatment with erlotinib (EGFR inhibitor) and a glutaminase inhibitor (CB-839) generates a metabolic crisis in EGFR mutant NSCLC cells, resulting in cell death and in rapid tumour regression in mouse NSCLC xenografts [64].